BioCentury
ARTICLE | Clinical News

Metabolic Solutions' TZD analog meets Phase IIb diabetes endpoint

June 12, 2012 1:34 AM UTC

Metabolic Solutions Development Co. (Kalamazoo, Mich.) said once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing fasting plasma glucose from baseline to week 12 vs. placebo in a Phase IIb trial to treat Type II diabetes. The once-daily 50 mg dose of MSDC-0160 missed the endpoint, while the active comparator once-daily 45 mg Actos pioglitazone also met the endpoint. All doses of MSDC-0160 significantly reduced HbA1c from baseline to week 12 vs. placebo. Specifically, the placebo-adjusted mean reductions in HbA1c were 0.39% for low-dose MSDC-0160, 0.79% for mid-dose MSDC-0160 and 0.86% for high-dose MSDC-0160. Actos led to a placebo-adjusted mean reduction in HbA1c of 0.98%. The double-blind, U.S. trial enrolled 266 patients. ...